These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

482 related articles for article (PubMed ID: 31739588)

  • 1. HDAC Inhibitors in Acute Myeloid Leukemia.
    San José-Enériz E; Gimenez-Camino N; Agirre X; Prosper F
    Cancers (Basel); 2019 Nov; 11(11):. PubMed ID: 31739588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential of Synthetic and Natural Compounds as Novel Histone Deacetylase Inhibitors for the Treatment of Hematological Malignancies.
    Pal D; Raj K; Nandi SS; Sinha S; Mishra A; Mondal A; Lagoa R; Burcher JT; Bishayee A
    Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Panobinostat for the treatment of acute myelogenous leukemia.
    Morabito F; Voso MT; Hohaus S; Gentile M; Vigna E; Recchia AG; Iovino L; Benedetti E; Lo-Coco F; Galimberti S
    Expert Opin Investig Drugs; 2016 Sep; 25(9):1117-31. PubMed ID: 27485472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic Modifiers in Myeloid Malignancies: The Role of Histone Deacetylase Inhibitors.
    Ungerstedt JS
    Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30304859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel epigenetic drug conjugating flavonoid and HDAC inhibitor confer suppression of acute myeloid leukemogenesis.
    Zhang J; Gao X; Wei M; Li Y; Yang G; Yang C; Yu L
    Clin Sci (Lond); 2021 Jul; 135(14):1751-1765. PubMed ID: 34282832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes.
    Stahl M; Gore SD; Vey N; Prebet T
    Expert Opin Investig Drugs; 2016; 25(3):307-17. PubMed ID: 26807602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic drug screen identifies the histone deacetylase inhibitor NSC3852 as a potential novel drug for the treatment of pediatric acute myeloid leukemia.
    Wiggers CRM; Govers AMAP; Lelieveld D; Egan DA; Zwaan CM; Sonneveld E; Coffer PJ; Bartels M
    Pediatr Blood Cancer; 2019 Aug; 66(8):e27785. PubMed ID: 31044544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia.
    Min C; Moore N; Shearstone JR; Quayle SN; Huang P; van Duzer JH; Jarpe MB; Jones SS; Yang M
    PLoS One; 2017; 12(1):e0169128. PubMed ID: 28060870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic therapy combinations in acute myeloid leukemia: what are the options?
    Bewersdorf JP; Shallis R; Stahl M; Zeidan AM
    Ther Adv Hematol; 2019; 10():2040620718816698. PubMed ID: 30719265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic therapies in acute myeloid leukemia: the role of hypomethylating agents, histone deacetylase inhibitors and the combination of hypomethylating agents with histone deacetylase inhibitors.
    Xu QY; Yu L
    Chin Med J (Engl); 2020 Mar; 133(6):699-715. PubMed ID: 32044818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic Activation of Plasmacytoid DCs Drives IFNAR-Dependent Therapeutic Differentiation of AML.
    Salmon JM; Todorovski I; Stanley KL; Bruedigam C; Kearney CJ; Martelotto LG; Rossello F; Semple T; Arnau GM; Zethoven M; Bots M; Bjelosevic S; Cluse LA; Fraser PJ; Litalien V; Vidacs E; McArthur K; Matthews AY; Gressier E; de Weerd NA; Lichte J; Kelly MJ; Hogg SJ; Hertzog PJ; Kats LM; Vervoort SJ; De Carvalho DD; Scheu S; Bedoui S; Kile BT; Lane SW; Perkins AC; Wei AH; Dominguez PM; Johnstone RW
    Cancer Discov; 2022 Jun; 12(6):1560-1579. PubMed ID: 35311997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone Deacetylase Inhibitors as Anticancer Drugs.
    Eckschlager T; Plch J; Stiborova M; Hrabeta J
    Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28671573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combinatorial effects of histone deacetylase inhibitors (HDACi), vorinostat and entinostat, and adaphostin are characterized by distinct redox alterations.
    Rivera-Del Valle N; Cheng T; Irwin ME; Donnella H; Singh MM; Chandra J
    Cancer Chemother Pharmacol; 2018 Mar; 81(3):483-495. PubMed ID: 29313067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair.
    Ye J; Zha J; Shi Y; Li Y; Yuan D; Chen Q; Lin F; Fang Z; Yu Y; Dai Y; Xu B
    Clin Epigenetics; 2019 Oct; 11(1):137. PubMed ID: 31590682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone deacetylase inhibitors induce proteolysis of activated CDC42-associated kinase-1 in leukemic cells.
    Mahendrarajah N; Paulus R; Krämer OH
    J Cancer Res Clin Oncol; 2016 Nov; 142(11):2263-73. PubMed ID: 27576506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone deacetylases 1 and 2 cooperate in regulating BRCA1, CHK1, and RAD51 expression in acute myeloid leukemia cells.
    Zhao J; Xie C; Edwards H; Wang G; Taub JW; Ge Y
    Oncotarget; 2017 Jan; 8(4):6319-6329. PubMed ID: 28030834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone deacetylase inhibitors reduce differentiating osteoblast-mediated protection of acute myeloid leukemia cells from cytarabine.
    Sterner RM; Kremer KN; Al-Kali A; Patnaik MM; Gangat N; Litzow MR; Kaufmann SH; Westendorf JJ; van Wijnen AJ; Hedin KE
    Oncotarget; 2017 Nov; 8(55):94569-94579. PubMed ID: 29212250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia.
    Baker A; Gregory GP; Verbrugge I; Kats L; Hilton JJ; Vidacs E; Lee EM; Lock RB; Zuber J; Shortt J; Johnstone RW
    Cancer Res; 2016 Mar; 76(5):1158-69. PubMed ID: 26627013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HDAC inhibitors: Promising agents for leukemia treatment.
    Deng Y; Cheng Q; He J
    Biochem Biophys Res Commun; 2023 Nov; 680():61-72. PubMed ID: 37722346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitors of LSD1 as a potential therapy for acute myeloid leukemia.
    Przespolewski A; Wang ES
    Expert Opin Investig Drugs; 2016 Jul; 25(7):771-80. PubMed ID: 27077938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.